Johnson said he wanted the wallpaper to have a handmade feel, like one is gazing upon an original artwork from the late 18th or early 19th centuries that showed country life in Great Britain.

If you’re looking to dramatically change a room but don’t want to spend a lot of money, time, or even be especially committed to the results, consider removable wallpaper — specifically the ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However ...

Johnson & Johnson has a strong business, several growth opportunities, and a safe dividend. The company does face headwinds, but it should be able to overcome them. Some might describe Johnson ...

Some might describe Johnson & Johnson's business as boring, but sometimes, that's not such a bad thing. Selling pharmaceutical products is a steady and reliable business even when the economy is ...

Johnson & Johnson is acquiring biopharmaceutical company Intra-Cellular Therapies for $14.6 billion. It has an approved depression and schizophrenia treatment that could generate $5 billion in ...

It’s nearly a year and a half since Johnson & Johnson split off its consumer-health arm to focus on pharmaceuticals and medical technology. Johnson & Johnson has wasted no time expanding its ...

From what we can see, insiders were net sellers in Johnson & Johnson's (NYSE:JNJ ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it.

High-rolling investors have positioned themselves bearish on Johnson & Johnson JNJ, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga ...

Gabby Jones / Bloomberg / Getty Images Johnson & Johnson is scheduled to report fourth-quarter earnings Wednesday morning, with analysts expecting sales and profits to grow year-over-year.

Johnson & Johnson (NYSE:JNJ) is scheduled to announce Q4 earnings results on Wednesday, January 22nd, before market open. Analysts expect a profit per share of $2.02, which is a decline of 11.8% ...

Johnson & Johnson said Monday it expects to accelerate sales growth beyond Wall Street expectations in the field of neuroscience with the $14.6 billion acquisition of Intra-Cellular Therapies Inc ...